Statin Citizen Petition: Coenzyme Effects Should Be Included In Label
This article was originally published in The Tan Sheet
Executive Summary
Statin labeling should be revised to carry a warning that drugs in the class deplete coenzyme Q10 levels and contribute to increased risk of myopathy, according to a citizen petition supplement filed with FDA
You may also be interested in...
CoQ10 Adjunctive Use With Rx Statins Encouraged In Citizen Petition
Supplementing statin drug use with coenzyme Q10 could help between 125,000 and 575,000 people avoid statin-induced liver dysfunction, cardiomyopathy or congestive heart failure, Julian Whitaker, MD, asserts in a May 29 citizen petition submitted to FDA
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands